Skip to main
TMO
TMO logo

TMO Stock Forecast & Price Target

TMO Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 29%
Buy 59%
Hold 12%
Sell 0%
Strong Sell 0%

Bulls say

Thermo Fisher Scientific is projected to experience steady revenue growth in its laboratory products and services segment, with an anticipated compound annual growth rate of 5.4% over the next three years. The company is poised to gain market share in the Contract Research Organization (CRO) space, benefiting from increasing trends in biopharma clinical trial outsourcing for both early-stage and late-stage drug development, as indicated by survey responses. Additionally, while analytical instruments revenue is expected to grow at a compound annual rate of 2.5%, this growth comes after a significantly higher growth rate of 6.2% from 2019 to 2024, reflecting a solid foundation for future stability and performance.

Bears say

From 2021 to 2024, Thermo Fisher Scientific experienced a significant decline in adjusted EBIT margin, dropping by approximately 830 basis points to 22.6%, largely due to a 940-basis-point reduction in adjusted gross margin. The company's adjusted gross margin decreased to 42.2%, which is about 420 basis points lower than the 46.4% gross margin recorded in 2019. This deterioration in margins raises concerns about the firm's profitability trends and overall financial health moving forward.

TMO has been analyzed by 17 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 59% recommend Buy, 12% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Thermo Fisher Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Thermo Fisher Scientific (TMO) Forecast

Analysts have given TMO a Buy based on their latest research and market trends.

According to 17 analysts, TMO has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $615.47, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $615.47, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Thermo Fisher Scientific (TMO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.